New hope for tough prostate cancer: drug combo targets bone tumors
NCT ID NCT03344211
First seen Nov 17, 2025 · Last updated Jun 17, 2026 · Updated 28 times
Summary
This study looks at men with advanced prostate cancer that no longer responds to hormone therapy and has spread to bones. It compares the drug enzalutamide alone versus enzalutamide plus a radioactive treatment (radium-223) to see how they affect the immune system and bone tumors. The goal is to find better ways to control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
City of Hope
Duarte, California, 91010, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.